Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-Label Study Evaluating the Safety and Efficacy of ST-067 in Combination With CD19-Directed CAR T-Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Conditions
Interventions
Vevoctadekin
Bone Marrow Aspiration
+11 more
Locations
1
United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
December 27, 2025
Primary Completion Date
October 4, 2030
Completion Date
October 4, 2043
Last Updated
January 14, 2026
NCT05755087
NCT05672251
NCT06905509
NCT06859008
NCT05052528
NCT02446457
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions